
    
      Approximately 276 patients will be enrolled in this study. Each patient will receive 1
      injection and be evaluated for efficacy and safety during a 6-month observation period.
      Randomization will be 1:1. The study is expected to be completed within 34 months, inclusive
      of enrollment and follow-up of all subjects.
    
  